ETAA1

Summary

ETAA1 (ETAA1 activator of ATR kinase, HGNC:24648) is a protein-coding gene on chromosome 2p14, encoding Ewing’s tumor-associated antigen 1 (Q9NY74). Replication stress response protein that accumulates at DNA damage sites and promotes replication fork progression and integrity.

Enables protein serine/threonine kinase activator activity. Involved in several processes, including positive regulation of protein serine/threonine kinase activity; regulation of cell cycle phase transition; and replication fork processing. Located in cytosol; nuclear lumen; and plasma membrane.

Source: NCBI Gene 54465 — RefSeq curated summary.

At a glance

• GWAS associations: 35
• Clinical variants (ClinVar): 132 total
• MANE Select transcript: NM_019002

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:24648
Approved symbol	ETAA1
Name	ETAA1 activator of ATR kinase
Location	2p14
Locus type	gene with protein product
Status	Approved
Aliases	ETAA16
Ensembl gene	ENSG00000143971
Ensembl biotype	protein_coding
OMIM	613196
Entrez	54465

Gene structure

Transcript identifiers

Ensembl transcripts: 8 — 6 protein_coding, 2 nonsense_mediated_decay

ENST00000272342, ENST00000462772, ENST00000644028, ENST00000645739, ENST00000854557, ENST00000925950, ENST00000925951, ENST00000925952

RefSeq mRNA: 1 — MANE Select: NM_019002 NM_019002

CCDS: CCDS1882

Canonical transcript exons

ENST00000272342 — 6 exons

Exon	Start	End
ENSE00000963000	67399550	67399626
ENSE00000963001	67402862	67402974
ENSE00000963004	67403225	67405335
ENSE00001006420	67409911	67412089
ENSE00001006421	67397333	67397671
ENSE00001247030	67399169	67399297

Expression profiles

Bgee: expression breadth ubiquitous, 224 present calls, max score 87.60.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 11.4103 / max 195.1946, expressed in 1751 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
20662	11.4103	1751

Top tissues by expression

259 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	87.60	gold quality
calcaneal tendon	UBERON:0003701	87.59	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	85.71	gold quality
germinal epithelium of ovary	UBERON:0001304	84.91	gold quality
visceral pleura	UBERON:0002401	83.30	gold quality
adrenal tissue	UBERON:0018303	83.21	gold quality
epithelium of nasopharynx	UBERON:0001951	82.85	silver quality
parietal pleura	UBERON:0002400	82.36	gold quality
pleura	UBERON:0000977	81.85	silver quality
right adrenal gland	UBERON:0001233	81.62	gold quality
gingival epithelium	UBERON:0001949	81.46	silver quality
left adrenal gland	UBERON:0001234	81.27	gold quality
right adrenal gland cortex	UBERON:0035827	81.11	gold quality
left adrenal gland cortex	UBERON:0035825	81.00	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.90	gold quality
palpebral conjunctiva	UBERON:0001812	79.90	gold quality
adrenal gland	UBERON:0002369	79.90	gold quality
adrenal cortex	UBERON:0001235	79.63	gold quality
body of pancreas	UBERON:0001150	79.32	gold quality
gingiva	UBERON:0001828	79.25	silver quality
stromal cell of endometrium	CL:0002255	79.07	gold quality
eye	UBERON:0000970	79.02	gold quality
ventricular zone	UBERON:0003053	79.01	gold quality
descending thoracic aorta	UBERON:0002345	78.91	gold quality
esophagus squamous epithelium	UBERON:0006920	78.87	silver quality
islet of Langerhans	UBERON:0000006	78.65	gold quality
right coronary artery	UBERON:0001625	78.65	gold quality
pancreas	UBERON:0001264	78.48	gold quality
tibia	UBERON:0000979	78.43	gold quality
endometrium	UBERON:0001295	78.11	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.75

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

38 targeting ETAA1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-548AW	99.99	72.57	3559
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-3617-3P	99.98	67.86	918
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-3671	99.90	73.04	3897
HSA-MIR-4496	99.88	68.89	2236
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-6124	99.87	69.78	3551
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-1323	99.83	69.89	2471
HSA-MIR-3617-5P	99.75	69.41	1968
HSA-MIR-641	99.75	69.35	1975
HSA-MIR-548O-3P	99.74	69.30	2228
HSA-MIR-3059-5P	99.70	69.93	2491
HSA-MIR-518A-5P	99.70	69.01	2209
HSA-MIR-527	99.70	69.01	2209
HSA-MIR-12124	99.68	69.17	2700
HSA-MIR-5093	99.67	69.26	2291
HSA-MIR-7157-5P	99.66	69.33	1829
HSA-MIR-3685	99.62	68.83	1621
HSA-MIR-4310	99.59	68.84	2527
HSA-MIR-142-5P	99.48	70.92	2416
HSA-MIR-5590-3P	99.48	70.91	2429
HSA-MIR-3140-5P	99.39	69.04	1136
HSA-MIR-4705	99.10	69.10	1091
HSA-MIR-3124-3P	98.87	68.95	2123
HSA-MIR-4477A	98.83	69.75	2952

Literature-anchored findings (GeneRIF, showing 9)

• results suggest that ETAA16 may function as a tumour-specific cell surface antigen in Ewing’s family of tumors (PMID:16003559)
• results reveal that ETAA1 is a novel RPA-interacting protein that promotes restart of stalled replication forks. (PMID:27601467)
• that parallel TopBP1- and ETAA1-mediated pathways underlie ATR activation and that their combined action is essential for coping with replication stress (PMID:27723717)
• ETAA1 acts as a direct ATR serine-threonine kinase protein activator (PMID:27723720)
• These our data suggest that ETAA1 is a new ATR activator involved in replication checkpoint control. (PMID:27818175)
• ETAA1 regulates mitotic ATR signaling and is required for proper chromosome alignment during metaphase and for a fully functional spindle assembly checkpoint response. (PMID:30755469)
• ETAA1 and TOPBP1 contain a predicted coiled-coil motif that is required for ATR activation in vitro and in cells. Mutation of the predicted coiled coils does not alter AAD oligomerization but does impair binding of the AADs to ATR. (PMID:30940728)
• ETAA1 may have an important role in protecting against genome instability arising from incompletely duplicated DNA via regulatory control of its ATR-stimulating potential (PMID:31615875)
• ATR activation is regulated by dimerization of ATR activating proteins. (PMID:33636182)

Cross-species orthologs

6 orthologs

Organism	Symbol	Gene ID
danio_rerio	etaa1a	ENSDARG00000074915
danio_rerio	etaa1b	ENSDARG00000078166
mus_musculus	Etaa1	ENSMUSG00000016984
rattus_norvegicus	Etaa1-ps1	ENSRNOG00000006185
rattus_norvegicus		ENSRNOG00000076406
rattus_norvegicus		ENSRNOG00000077122

Protein

Protein identifiers

Ewing’s tumor-associated antigen 1 — Q9NY74 (reviewed: Q9NY74)

Alternative names: Ewing’s tumor-associated antigen 16

All UniProt accessions (4): Q9NY74, A0A2R8Y6Y8, A0A2R8Y7B6, A0A2R8YEV8

UniProt curated annotations — full annotation on UniProt →

Function. Replication stress response protein that accumulates at DNA damage sites and promotes replication fork progression and integrity. Recruited to stalled replication forks via interaction with the RPA complex and directly stimulates ATR kinase activity independently of TOPBP1. Probably only regulates a subset of ATR targets.

Subunit / interactions. Interacts (via RBM1 motif) with RPA1. Interacts (via RBM2 motif) with RPA2. Interacts (via the ATR-activation domain motif) with ATR.

Subcellular location. Nucleus.

Tissue specificity. Expressed at high levels in the brain, liver kidney and Ewing tumor cell lines.

Post-translational modifications. Phosphorylated by ATR.

Domain organisation. The RBM1 (RPA1-binding, also named RPA70N-binding) motif mediates interaction with RPA1. The RBM2 (RPA2-binding, also named RPA32C-binding) motif mediates interaction with RPA2. The ATR-activation domain (AAD) motif is required to bind and activate ATR.

RefSeq proteins (1): NP_061875* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR029406	ETAA1	Family

Pfam: PF15350

UniProt features (30 total): cross-link 7, sequence variant 5, region of interest 3, compositionally biased region 3, modified residue 3, short sequence motif 3, mutagenesis site 2, chain 1, sequence conflict 1, helix 1, coiled-coil region 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
8JZV	X-RAY DIFFRACTION	1.5

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NY74-F1	49.74	0.05

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (10): 186, 464, 833, 85, 414, 442, 480, 507, 533, 535

Mutagenesis-validated functional residues (2):

Position	Phenotype
106–107	reduced ability to promote replication fork progression and integrity following dna damage.
107	reduced interaction with atr.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 155 (showing top): GOBP_DNA_TEMPLATED_DNA_REPLICATION_MAINTENANCE_OF_FIDELITY, GOBP_REGULATION_OF_CELL_CYCLE_CHECKPOINT, GOBP_REGULATION_OF_PHOSPHORYLATION, chr2p14, GOBP_CELL_CYCLE_PHASE_TRANSITION, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, KENNY_CTNNB1_TARGETS_UP, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY, GOBP_MITOTIC_G2_M_TRANSITION_CHECKPOINT, GOBP_REGULATION_OF_CELL_CYCLE_G2_M_PHASE_TRANSITION, GOMF_KINASE_ACTIVATOR_ACTIVITY, GOCC_NUCLEAR_REPLICATION_FORK, GOBP_POSITIVE_REGULATION_OF_CATALYTIC_ACTIVITY, GOBP_POSITIVE_REGULATION_OF_MOLECULAR_FUNCTION

GO Biological Process (7): DNA repair (GO:0006281), DNA damage response (GO:0006974), replication fork processing (GO:0031297), mitotic G2/M transition checkpoint (GO:0044818), positive regulation of protein serine/threonine kinase activity (GO:0071902), regulation of DNA damage checkpoint (GO:2000001), G2/M transition of mitotic cell cycle (GO:0000086)

GO Molecular Function (2): protein serine/threonine kinase activator activity (GO:0043539), protein binding (GO:0005515)

GO Cellular Component (6): nucleoplasm (GO:0005654), cytosol (GO:0005829), plasma membrane (GO:0005886), nuclear speck (GO:0016607), nuclear replication fork (GO:0043596), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein serine/threonine kinase activity	2
cellular anatomical structure	2
DNA metabolic process	1
DNA damage response	1
cellular response to stress	1
DNA-templated DNA replication maintenance of fidelity	1
mitotic cell cycle checkpoint signaling	1
negative regulation of G2/M transition of mitotic cell cycle	1
positive regulation of protein kinase activity	1
regulation of protein serine/threonine kinase activity	1
DNA damage checkpoint signaling	1
regulation of cellular response to stress	1
regulation of cell cycle checkpoint	1
mitotic cell cycle	1
mitotic cell cycle phase transition	1
cell cycle G2/M phase transition	1
protein kinase activator activity	1
binding	1
nuclear lumen	1
cytoplasm	1
membrane	1
cell periphery	1
nuclear ribonucleoprotein granule	1
nuclear chromosome	1
nucleus	1
replication fork	1
CMG complex	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

2627 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ETAA1	ATRIP	Q8WXE1	828
ETAA1	TOPBP1	Q92547	825
ETAA1	SMARCAL1	Q9NZC9	661
ETAA1	RPA2	P15927	640
ETAA1	DNAAF10	Q96MX6	634
ETAA1	STN1	Q9H668	617
ETAA1	RAD9A	Q99638	616
ETAA1	HUS1	O60921	612
ETAA1	RAD17	O75943	576
ETAA1	CHEK1	O14757	573
ETAA1	FBXO48	Q5FWF7	504
ETAA1	RPAIN	Q86UA6	489
ETAA1	ATR	Q13535	479
ETAA1	BRD10	Q5HYC2	477
ETAA1	TIPIN	Q9BVW5	470

IntAct

15 interactions, top by confidence:

A	B	Type	Score
GAMMAHV.ORF10	ETAA1	psi-mi:“MI:0915”(physical association)	0.370
ETAA1	TARS3	psi-mi:“MI:0914”(association)	0.350
PB2	HAX1	psi-mi:“MI:0914”(association)	0.350
PB1	ESYT2	psi-mi:“MI:0914”(association)	0.350
PB2	PIK3R2	psi-mi:“MI:0914”(association)	0.350
PB2	ESYT2	psi-mi:“MI:0914”(association)	0.350
PB2	IPO5	psi-mi:“MI:0914”(association)	0.350
M		psi-mi:“MI:0914”(association)	0.350
HSPA4	HSPA8	psi-mi:“MI:0914”(association)	0.350
CFAP184	TARS3	psi-mi:“MI:0914”(association)	0.350
BRCA1	SMCHD1	psi-mi:“MI:2364”(proximity)	0.270
GABARAPL1	BLTP3B	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (180): ETAA1 (Affinity Capture-MS), ZBTB48 (Affinity Capture-MS), HIST1H4A (Affinity Capture-MS), SUPT16H (Affinity Capture-MS), TARSL2 (Affinity Capture-MS), ETAA1 (Affinity Capture-MS), ETAA1 (Proximity Label-MS), ETAA1 (Affinity Capture-MS), RPA1 (Affinity Capture-Western), ETAA1 (Co-crystal Structure), RPA1 (Affinity Capture-MS), RPA2 (Affinity Capture-MS), RPA3 (Affinity Capture-MS), BLM (Affinity Capture-MS), RMI1 (Affinity Capture-MS)

ESM2 similar proteins: A2RRX6, A4IFU8, A5D7U0, A5PK21, A6QNQ6, B0BM16, B1H1S4, B1WC58, O43303, P16128, P51816, Q08DI1, Q14207, Q15398, Q28FY7, Q2M2Z5, Q32PP1, Q3UHX0, Q49A88, Q569L8, Q5BQN8, Q5FBB7, Q5HZI1, Q5QGS0, Q5R9I1, Q5RD97, Q5SVT3, Q5W0B1, Q6GNV6, Q6NZG4, Q6P0N0, Q6PDM4, Q6ZU52, Q7SZL5, Q7ZZH7, Q80WQ8, Q80YR6, Q86WS4, Q8CDD9, Q8IYA6

Diamond homologs: Q08DI1, Q5SVT3, Q9NY74

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

132 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	109
Likely benign	12
Benign	3

Top pathogenic / likely-pathogenic (0)

SpliceAI

1240 predictions. Top by Δscore:

Variant	Effect	Δscore
2:67399294:T:G	donor_gain	1.0000
2:67399545:TTTA:T	acceptor_loss	1.0000
2:67399546:TTAG:T	acceptor_loss	1.0000
2:67399547:TA:T	acceptor_loss	1.0000
2:67399549:G:A	acceptor_loss	1.0000
2:67399622:CTCAG:C	donor_loss	1.0000
2:67399623:TCAG:T	donor_loss	1.0000
2:67399624:CAG:C	donor_loss	1.0000
2:67399625:AGG:A	donor_loss	1.0000
2:67399626:GGT:G	donor_loss	1.0000
2:67399627:G:C	donor_loss	1.0000
2:67399628:T:A	donor_loss	1.0000
2:67400416:GAGTT:G	donor_gain	1.0000
2:67402506:A:AG	donor_gain	1.0000
2:67402851:A:AG	acceptor_gain	1.0000
2:67402852:T:G	acceptor_gain	1.0000
2:67402854:T:TA	acceptor_gain	1.0000
2:67402973:AA:A	donor_gain	1.0000
2:67402975:G:GG	donor_gain	1.0000
2:67402980:T:G	donor_gain	1.0000
2:67409909:A:AG	acceptor_gain	1.0000
2:67409910:G:GG	acceptor_gain	1.0000
2:67397535:G:GA	donor_gain	0.9900
2:67397546:G:GT	donor_gain	0.9900
2:67397547:G:T	donor_gain	0.9900
2:67397651:GC:G	donor_gain	0.9900
2:67397654:G:GG	donor_gain	0.9900
2:67397660:G:GG	donor_gain	0.9900
2:67397670:GG:G	donor_gain	0.9900
2:67397671:GG:G	donor_gain	0.9900

AlphaMissense

6196 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
2:67399264:T:A	W107R	0.996
2:67399264:T:C	W107R	0.996
2:67402898:T:A	W156R	0.996
2:67402898:T:C	W156R	0.996
2:67399266:G:C	W107C	0.994
2:67399266:G:T	W107C	0.994
2:67403263:T:C	L194P	0.993
2:67402900:G:C	W156C	0.992
2:67402900:G:T	W156C	0.992
2:67403254:T:C	L191P	0.992
2:67403274:T:C	F198L	0.991
2:67403276:T:A	F198L	0.991
2:67403276:T:G	F198L	0.991
2:67403265:G:C	A195P	0.990
2:67399613:G:C	R139P	0.989
2:67403275:T:C	F198S	0.989
2:67399607:T:A	V137D	0.988
2:67409970:G:C	A905P	0.988
2:67403266:C:A	A195D	0.985
2:67409980:G:C	R908P	0.985
2:67399595:T:C	I133T	0.984
2:67399265:G:C	W107S	0.983
2:67399616:T:G	I140S	0.983
2:67399595:T:G	I133S	0.982
2:67404522:T:C	C614R	0.982
2:67409984:A:C	R909S	0.982
2:67409984:A:T	R909S	0.982
2:67409963:A:C	R902S	0.981
2:67409963:A:T	R902S	0.981
2:67403538:T:C	F286L	0.979

dbSNP variants (sampled 300 via entrez): RS1000051421 (2:67395700 A>G), RS1000233529 (2:67401938 A>G), RS1000813346 (2:67407004 G>A), RS1000835627 (2:67400380 G>A), RS1001277180 (2:67396040 A>C,T), RS1001348797 (2:67399978 T>C), RS1001580768 (2:67397992 G>C,T), RS1001691796 (2:67404980 C>T), RS1001991630 (2:67411417 C>CTACA), RS1002389208 (2:67407344 G>A), RS1002675613 (2:67404073 C>T), RS1003058428 (2:67411100 A>G), RS1003310237 (2:67402858 A>C,G), RS1003357068 (2:67397250 A>C), RS1003364138 (2:67403236 A>G)

Disease associations

OMIM: gene MIM:613196 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

35 associations (top):

Study	Trait	p-value
GCST002126_18	Periodontitis (CDC/AAP)	8.000000e-06
GCST002138_5	Waist-hip ratio	4.000000e-06
GCST002788_2	Milk allergy	2.000000e-06
GCST002792_2	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia	1.000000e-08
GCST002991_14	Pancreatic cancer	3.000000e-09
GCST003807_1	Systolic blood pressure response to hydrochlorothiazide in hypertension	7.000000e-06
GCST003983_23	Male-pattern baldness	6.000000e-12
GCST003992_49	Photic sneeze reflex	1.000000e-11
GCST004518_7	Waist-to-hip ratio adjusted for body mass index	5.000000e-06
GCST004549_13	Endometriosis	3.000000e-08
GCST004549_31	Endometriosis	3.000000e-07
GCST004567_137	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)	1.000000e-06
GCST004567_38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)	5.000000e-07
GCST004567_59	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)	1.000000e-07
GCST004567_68	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction)	3.000000e-09
GCST004576_127	Waist-to-hip ratio adjusted for body mass index	9.000000e-08
GCST004576_128	Waist-to-hip ratio adjusted for body mass index	3.000000e-09
GCST004576_96	Waist-to-hip ratio adjusted for body mass index	3.000000e-08
GCST004576_97	Waist-to-hip ratio adjusted for body mass index	8.000000e-09
GCST004578_105	Waist-to-hip ratio adjusted for BMI in active individuals	1.000000e-07
GCST004578_114	Waist-to-hip ratio adjusted for BMI in active individuals	3.000000e-07
GCST004578_14	Waist-to-hip ratio adjusted for BMI in active individuals	4.000000e-07
GCST004578_70	Waist-to-hip ratio adjusted for BMI in active individuals	4.000000e-08
GCST004578_88	Waist-to-hip ratio adjusted for BMI in active individuals	1.000000e-07
GCST004744_56	Lung adenocarcinoma	2.000000e-06
GCST004744_69	Lung adenocarcinoma	3.000000e-06
GCST004748_83	Lung cancer	1.000000e-06
GCST004748_84	Lung cancer	1.000000e-07
GCST004749_94	Lung cancer in ever smokers	4.000000e-07
GCST004749_95	Lung cancer in ever smokers	1.000000e-07

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0004343	waist-hip ratio
EFO:0007019	milk allergy measurement
EFO:0006944	systolic blood pressure change measurement
EFO:0007887	autosomal dominant compelling helio-ophthalmic outburst syndrome
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008002	physical activity measurement
EFO:0009819	comparative body size at age 10, self-reported
EFO:0008039	BMI-adjusted hip circumference

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

36 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, affects cotreatment, increases abundance	3
perfluorooctane sulfonic acid	decreases expression	2
Tobacco Smoke Pollution	decreases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
aristolochic acid I	decreases expression	1
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
FR900359	affects phosphorylation	1
TAK-243	increases sumoylation	1
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation	1
salinomycin	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
manganese chloride	increases abundance, affects cotreatment, decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
ferrous chloride	decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	decreases expression	1
Air Pollutants	decreases expression, increases abundance	1
Arsenic	affects cotreatment, decreases expression, increases abundance	1
Cisplatin	decreases expression	1
Estradiol	affects expression	1
Manganese	increases abundance, affects cotreatment, decreases expression	1
Silver	decreases expression	1
Testosterone	decreases expression	1
Thiram	decreases expression	1
Urethane	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.